 |
| Lentiviral Vectors Market |
Lentiviral vectors are experimental gene therapy treatments used to deliver healthy genes into a patient's cells and tissues to treat disease. They have emerged as an efficient tool for stable gene transfer due to their ability to efficiently transduce non-proliferating cells. Lentiviral vectors show great promise for treating inherited disorders such as hemophilia, lysosomal storage diseases, and metabolic disorders.
The global Lentiviral Vectors Market is estimated to be valued at US$ 292 Mn in 2023 and is expected to
exhibit a CAGR of 18% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
The increasing development and approval of gene therapies has accelerated the
growth of the lentiviral vectors market. For instance, in the year 2022, the
U.S. FDA approved Libmeldy by Orchard Therapeutics to treat early-onset
metachromatic leukodystrophy (MLD), which utilizes lentiviral vector as a gene
delivery system. Moreover, there is a growing interest among biopharma
companies to leverage lentiviral vectors for developing next-generation cell
and gene therapies, as lentiviral vectors allow stable integration and
long-term expression of therapeutic transgenes in both dividing and
non-dividing cells. This is expected to drive the demand for lentiviral vectors
over the forecast period.
Segment
Analysis
The global lentiviral vectors market is dominated by the research segment which
accounts for over 55% share. Research activities involving lentiviral vectors
are high owing to its ability to integrate into the host genome and offers long
term gene expression. It is widely used in research areas such as gene therapy,
stem cell research, oncology and genetic engineering.
Key Takeaways
The global Lentiviral
Vectors Market Growth is expected to witness high growth over the
forecast period of 2023 to 2030. The global Lentiviral Vectors Market is
estimated to be valued at US$ 292 Mn in 2023 and is expected to exhibit a CAGR
of 18% over the forecast period 2023 to 2030.
Regional analysis
North America dominates the global lentiviral vectors market with over 40%
share due to high technological advancements and increasing research funding in
the region. Growing number of clinical research for developing potential gene
therapies and vaccines against various diseases such as cancer is also boosting
the market growth. Asia Pacific is expected to witness fastest growth over the
coming years supported by growing biomedical research in emerging economies
such as China and India.
Key players
Key players operating in the lentiviral vectors market are Thermo Fisher
Scientific Inc., Sirion-Biotech GmbH (Revvity), Vector Biolabs, OriGene
Technologies, Inc., SignaGen Laboratories, Sino Biological, Inc., Takara Bio
Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, bluebird bio, Inc.,
Cellomics Technology, LLC., Virica Biotech, Oxford Biomedica, and ANDELYN
BIOSCIENCES.
Comments
Post a Comment